{{medical}}
{{Drugbox
| type = mab
| image = 
| alt = 
| mab_type = mab
| source = u
| target = [[白细胞介素-4|白细胞介素-4]]受體α（receptor alpha）
| tradename = 达必妥<br>Dupixent
| Drugs.com = 
| MedlinePlus = 
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category=  
| legal_AU = S4
| legal_CA = 
| legal_UK = 
| legal_US = Rx only
| legal_status = 
| routes_of_administration = 注射
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
| CAS_number = 1190264-60-8
| ATC_prefix = D11
| ATC_suffix = AH05
| PubChem = 
| DrugBank = DB12159
| ChemSpiderID = 無
| KEGG = D10354
| UNII = 420K487FSG
| C=6512 | H=10066 | N=1730 | O=2052 | S=46
}}'''達必妥'''（{{lang-en|Dupixent}}）是一种[[单克隆抗体|单克隆抗体]]藥物，可用于治療{{en-link|过敏性疾病|Atopy}}，如[[皮膚炎|皮膚炎（特应性皮炎）]]、[[哮喘|哮喘]]和[[鼻息肉|鼻息肉]]导致的[[鼻竇炎|鼻窦炎]]。<ref>[http://www.ama-assn.org/resources/doc/usan/dupilumab.pdf "Statement On A Nonproprietary Name Adopted By The USAN Council - Dupilumab"], [[美国医学会|American Medical Association]]. {{Wayback|url=http://www.ama-assn.org/resources/doc/usan/dupilumab.pdf |date=20200408192435 }}</ref><ref name="FDA2017">{{Cite web|title=FDA approves new eczema drug Dupixent|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm549078.htm|date=2019-09-10|publisher=FDA|accessdate=2020-07-24|archive-date=2019-04-23|archive-url=https://web.archive.org/web/20190423192111/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm549078.htm|dead-url=no}}</ref><ref>{{Cite web|title=FDA approves first treatment for chronic rhinosinusitis with nasal polyps|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-rhinosinusitis-nasal-polyps|accessdate=27 June 2019|date=26 June 2019|publisher=FDA|language=en|archive-date=2020-12-29|archive-url=https://web.archive.org/web/20201229023614/https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-rhinosinusitis-nasal-polyps|dead-url=no}}</ref><ref name=":2">{{Cite web|title=FDA label|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761055s007lbl.pdf|accessdate=|author=|date=|first=|work=FDA official site|archiveurl=https://web.archive.org/web/20210403170332/https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761055s007lbl.pdf|archivedate=2021-04-03|dead-url=no}}</ref>該藥物的副作用會誘發[[过敏|过敏]]、[[唇瘡|唇瘡]]和[[角膜炎|角膜炎]]。<ref name="FDA2017" /> 該藥品由[[再生元製藥|再生元製藥]]和[[健赞|健赞]]研發。<ref>{{Cite web|title=Sanofi - Commercial collaboration|url=http://en.sanofi.com/partners/developing_marketing_innovative_solutions/commercial_collaboration/commercial_collaboration.aspx|accessdate=2017-03-09|publisher=Sanofi|language=en|archive-date=2017-11-08|archive-url=https://web.archive.org/web/20171108102850/http://en.sanofi.com/partners/developing_marketing_innovative_solutions/commercial_collaboration/commercial_collaboration.aspx|dead-url=no}}</ref><ref>{{Cite web|title=A powerful research and development engine|url=https://www.regeneron.com/pipeline|accessdate=2017-03-09|publisher=www.regeneron.com|archive-date=2019-04-30|archive-url=https://web.archive.org/web/20190430095722/https://www.regeneron.com/pipeline|dead-url=no}}</ref>2017年，美国[[美国食品药品监督管理局|食品和药物管理局]]批准其可用於治療中度至重度特应性皮炎。2018年底，又被美国[[美国食品药品监督管理局|食品和药物管理局]]批准用於治療哮踹。<ref name=":2" /> 

== 参考文献 ==
{{Reflist}}

[[Category:赛诺菲|Category:赛诺菲]]
[[Category:突破療法|Category:突破療法]]
[[Category:单克隆抗体类|Category:单克隆抗体类]]